Financial Results & Outlook for FY2012

Transcription

1 Financial Results & Outlook for May 10, 2012

2 (Cautionary Statement) Statements made in this material with respect to Sumitomo Chemical s current plans, estimates, strategies and beliefs that are not historical facts are forward-looking statements about the future performance of Sumitomo Chemical. These statements are based on management s assumptions and beliefs in light of the information currently available to it, and involve risks and uncertainties. The important factors that could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to, general economic conditions in Sumitomo Chemical s markets; demand for, and competitive pricing pressure on, Sumitomo Chemical s products in the marketplace; Sumitomo Chemical s ability to continue to win acceptance for its products in these highly competitive markets; and movements of currency exchange rates.

3 1.Consolidated Financial Results for FY2011 Ended March 31, 2012 Financial Summary Net Sales by Business Segments Operating Income by Business Segments Major Cost Elements Extraordinary Gains / Losses Consolidated Balance Sheets Consolidated Statements of Cash Flows Major Subsidiaries 2. Outlook for Financial Summary Net Sales by Business Segments Operating Income by Business Segments Net Sales and Operating Income by Business Segments Contents Major Cost Elements Consolidated Statements of Cash Flows (Reference: Segment Information) Capital Expenditures by Business Segments Depreciation and Amortization by Business Segments Research & Development Expenses by Business Segments Estimated Capital Expenditures by Business Segments Estimated Depreciation and Amortization by Business Segments Estimated Research & Development Expenses by Business Segments

4 1.Consolidated Financial Results for FY2011 Ended March 31,

5 Financial Summary FY2010 FY2011 Difference Growth Rate Net Sales 1, , % Operating Income % (Equity in earnings of affiliates, included in ordinary income) (Net loss on foreign currency transactions, included in ordinary income) (10.8) (2.0) % (-6.6) (-3.7) (2.9) - Ordinary Income % Net Income % ROE 4.5% 1.1% Naphtha Price (yen/kl) 47,500 54,900 Exchange Rate (yen/us$)

6 Net Sales by Business Segments FY2010 FY2011 Difference Growth Rate Sales Price Shipping Volume Foreign Currency Conversion Basic Chemicals % Petrochemicals % IT-related Chemicals % Health & Crop Sciences % Pharmaceuticals % Others & Adjustments % Total 1, , % Overseas Operations 1, , % *Segment information of the previous fiscal year is reclassified in accordance with the change in reported segments. 3

7 Operating Income by Business Segments Basic Chemicals Petro- Chemicals IT-related Chemicals Health & Crop Sciences Pharmaceuticals Others & Adjustments Operating Income FY2010 FY2011 Difference Price Sales Price Purchase Price Cost Shipping Volume and Other Total Total

8 Major Cost Elements FY2010 FY2011 Difference Labor Costs Maintenance Costs Depreciation and Amortization Research & Development Expenses Capital Expenditures Number of employees (as of March 31) 29,382 29,

9 Extraordinary Gains / Losses FY2010 FY2011 Difference Gain on sale of investment securities Gain on sale of property, plant and equipment Extraordinary Gains Equity in losses of affiliates Restructuring charges Impairment loss Environmental expenses Loss on disaster Extraordinary Losses Extraordinary Gains / Losses

10 Consolidated Balance Sheets 31-Mar Mar-12 Difference 31-Mar Mar-12 Difference Current Assets 1, , Liabilities 1, , Cash and cash equivalents Trade notes and accounts receivable Trade notes and accounts payable Interest-bearing Liabilities 1, , Inventories Others Others Net Assets Non-current Assets 1, , Shareholders' equity Property, plant and equipment Accumulated other comprehensive income Intangible assets Minority interests Investment and other assets Total 2, , Total 2, , Shareholders' equity ratio 22.1% 20.8% -1.3% 7

11 Consolidated Statements of Cash Flows FY2010 FY2011 Difference Cash flows from operating activities Cash flows from investing activities Free cash flows Cash flows from financing activities Effect of exchange rate changes on cash and cash equivalents Net change in cash and cash equivalents Cash and cash equivalents at end of year

12 Major Subsidiaries Company The Polyolefin Company (Singapore) (millions of USD) Petrochemical Corporation of Singapore (millions of USD) Rabigh Refining and Petrochemical Company (millions of SAR) FY2010 FY2011 1,342 1,512 3,023 3,465 46,838 53,377 Dongwoo Fine-Chem 2,249 2,153 (billions of KRW) Valent U.S.A. and Subsidiaries (millions of USD) Net Sales 9 Profit Trends Decreased due to lower sales volume caused by weakened demand and margin erosion Decreased due to margin erosion Decreased due to non-operating income incurred in the previous year Decreased due to lower selling prices and unfavorable currencyexchange trends Increased due to higher sales volume despite lower selling price

13 2. Outlook for 10

14 Financial Summary FY2011 (estimated) Difference Growth Rate Net Sales 1, , % Operating Income % (Equity in earnings of affiliates, included in ordinary income) (2.0) (16.0) (14.0) 705.6% Ordinary Income % Net Income % ROE 1.1% 7.8% Naphtha Price (yen/kl) 54,900 65,000 Exchange Rate (yen/us$)

15 Net Sales by Business Segments FY2011 (estimated) Difference Growth Rate Sales Price Shipping Volume Foreign Currency Conversion Basic Chemicals % Petrochemicals % IT-related Chemicals % Health & Crop Sciences % Pharmaceuticals % Others % Total 1, , %

16 Operating Income by Business Segments Basic Chemicals Petro- Chemicals IT-related Chemicals Health & Crop Sciences Pharmaceuticals Others & Adjustments Operating Income FY2011 (estimated) Difference Price Sales Price Purchase Price Cost Shipping Volume and Other Total Total

17 Net Sales and Operating Income by Business Segments Net Sales Operating Income Basic Chemicals Petro- Chemicals IT-related Chemicals Health & Crop Sciences Pharmaceuticals Others & Adjustments 1st Half of 2nd Half of (estimated) 1st Half of 2nd Half of (estimated) Total 1, , ,

18 Major Cost Elements FY2011 (estimated) Difference Labor Costs Maintenance Costs Depreciation and Amortization Research & Development Expenses Capital Expenditures Number of employees (as of March 31) 29,839 31,300 1,461 15

19 Consolidated Statements of Cash Flows FY2011 (estimated) Difference Cash flows from operating activities Cash flows from investing activities Free cash flows Cash flows from financing activities Effect of exchange rate changes on cash and cash equivalents Net change in cash and cash equivalents Interest-Bearing Debt Balance 1, ,

20 (Reference: Segment Information) 17

21 Capital Expenditures by Business Segments FY2010 FY2011 Difference Basic Chemicals Petrochemicals IT-related Chemicals Health & Crop Sciences Pharmaceuticals Others & Adjustments Total

22 Depreciation and Amortization by Business Segments FY2010 FY2011 Difference Basic Chemicals Petrochemicals IT-related Chemicals Health & Crop Sciences Pharmaceuticals Others & Adjustments Total

23 Research & Development Expenses by Business Segments FY2010 FY2011 Difference Basic Chemicals Petrochemicals IT-related Chemicals Health & Crop Sciences Pharmaceuticals Others & Adjustments Total

24 Estimated Capital Expenditures by Business Segments FY2011 (estimated) Difference Basic Chemicals Petrochemicals IT-related Chemicals Health & Crop Sciences Pharmaceuticals Others & Adjustments Total

25 Estimated Depreciation and Amortization by Business Segments FY2011 (estimated) Difference Basic Chemicals Petrochemicals IT-related Chemicals Health & Crop Sciences Pharmaceuticals Others & Adjustments Total

26 Estimated Research & Development Expenses by Business Segments FY2011 (estimated) Difference Basic Chemicals Petrochemicals IT-related Chemicals Health & Crop Sciences Pharmaceuticals Others & Adjustments Total